Table 2.
Patient demographics of the pooled analysis data set
| Description | Unit | Value |
|---|---|---|
| Sex (male/female) | n | 229/1359 |
| Ethnicity | ||
| Caucasian | n | 1253 |
| Black/African American | n | 83 |
| Asian/Pacific Islander | n | 23 |
| Japanese | n | 96 |
| Other/unknown | n | 133 |
| Previous chemotherapy (yes/no) | n | 1527/61 |
| Previous Pt-containing chemotherapy (yes/no) | n | 446/1142 |
| Previous radiotherapy (yes/no) | n | 1212/375 |
| Previous hormonal therapy (yes/no) | n | 923/761 |
| Blood transfusions (yes/no) | n | 161/1523 |
| Received G-CSF (yes/no) | n | 382/1302 |
| Age [median (IQR)] | years | 58.0 (49.0–66.0) |
| Bodyweight [median (IQR)] | kg | 67.7* (59.0–77.6) |
| Body surface area [median (IQR)] | m2 | 1.73 (1.61–1.86) |
| Height [median (IQR)] | cm | 162 (157–168) |
| Albumin [median (IQR)] | g dl−1 | 3.90† (3.6–4.27) |
| Alkaline phosphatase [median (IQR)] | IU l−1 | 118‡ (82.0–206) |
| Alanine transaminase [median (IQR)] | IU l−1 | 25.0 (17.0–39.6) |
| Aspartate transaminase [median (IQR)] | IU l−1 | 30.0 (22.0–46.0) |
| Bilirubin [median (IQR)] | mg dl−1 | 0.50§ (0.40–0.70) |
| Serum creatinine [median (IQR)] | mg dl−1 | 0.80 (0.68–0.91) |
| Lactate dehydrogenase [median (IQR)] | IU l−1 | 328¶ (211–486) |
| Platelets [median (IQR)] | 109 l−1 | 260 (209–326) |
| Protein [median (IQR)] | g dl−1 | 7.1 (6.7–7.5) |
Abbreviations are as follows: G-CSF, granulocyte colony-stimulating factor; IQR, interquartile range; Pt, platinum-containing. Covariates were missing for <6% of subjects for the first or last observation over time per patient, and <13% for intermediate missing observations over time per patient. For <6% of subjects, all covariates were missing, when excluding lactate dehydrogenase (7.82%) and platelets (8.98%). The scaling value used in the covariate model deviated from the median and was set at *70 kg, †4, ‡100, §2 and ¶238.